|

Placebo for Ocrelizumab Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 4: 1

Top Sponsors

  • National Institute of Allergy and Infectious Diseases (NIAID)1

Indications

  • Multiple Sclerosis1

New Haven, Connecticut1 trial

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Yale School of Medicine

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.